SG11201707284PA - Kv1.3 inhibitors and their medical application - Google Patents
Kv1.3 inhibitors and their medical applicationInfo
- Publication number
- SG11201707284PA SG11201707284PA SG11201707284PA SG11201707284PA SG11201707284PA SG 11201707284P A SG11201707284P A SG 11201707284PA SG 11201707284P A SG11201707284P A SG 11201707284PA SG 11201707284P A SG11201707284P A SG 11201707284PA SG 11201707284P A SG11201707284P A SG 11201707284PA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- medical application
- medical
- application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15159080 | 2015-03-13 | ||
PCT/EP2016/055451 WO2016146583A1 (fr) | 2015-03-13 | 2016-03-14 | Inhibiteurs de kv1.3 et leur application médicale |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201707284PA true SG11201707284PA (en) | 2017-10-30 |
Family
ID=52736854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201707284PA SG11201707284PA (en) | 2015-03-13 | 2016-03-14 | Kv1.3 inhibitors and their medical application |
Country Status (27)
Country | Link |
---|---|
US (4) | US10822345B2 (fr) |
EP (1) | EP3268374B1 (fr) |
JP (1) | JP6506409B2 (fr) |
KR (1) | KR20170137056A (fr) |
CN (1) | CN107548397B (fr) |
AU (1) | AU2016232338B2 (fr) |
BR (1) | BR112017019439A2 (fr) |
CA (1) | CA2979503A1 (fr) |
CY (1) | CY1122470T1 (fr) |
DK (1) | DK3268374T3 (fr) |
EA (1) | EA037194B1 (fr) |
ES (1) | ES2762938T3 (fr) |
HK (1) | HK1243997B (fr) |
HR (1) | HRP20192258T1 (fr) |
IL (1) | IL254391B (fr) |
LT (1) | LT3268374T (fr) |
MX (1) | MX2017011650A (fr) |
PH (1) | PH12017501652B1 (fr) |
PL (1) | PL3268374T3 (fr) |
PT (1) | PT3268374T (fr) |
RS (1) | RS59758B1 (fr) |
SG (1) | SG11201707284PA (fr) |
SI (1) | SI3268374T1 (fr) |
TW (1) | TWI701249B (fr) |
UA (1) | UA121493C2 (fr) |
WO (1) | WO2016146583A1 (fr) |
ZA (1) | ZA201705561B (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3133065A1 (fr) | 2015-08-21 | 2017-02-22 | Merck Patent GmbH | Composés de dispositifs optiquement actifs |
EP3363786A1 (fr) | 2017-02-15 | 2018-08-22 | Merck Patent GmbH | Composés de dispositifs optiquement actifs |
EP3363793A1 (fr) | 2017-02-15 | 2018-08-22 | Merck Patent GmbH | Composés hydrophobes pour dispositifs optiquement actifs |
AU2018335838B2 (en) | 2017-09-20 | 2022-06-30 | Lead Discovery Center Gmbh | Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer |
US10703735B2 (en) | 2018-07-25 | 2020-07-07 | Lead Discovery Center Gmbh | 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer |
CN112533916B (zh) * | 2018-09-07 | 2022-05-20 | 正大天晴药业集团股份有限公司 | 一种作用于crbn蛋白的三并环类化合物 |
EP3941906B1 (fr) | 2019-03-20 | 2023-05-03 | Lead Discovery Center GmbH | Dérivés de quinoline, leurs procédés de préparation et leurs utilisations pour le traitement du cancer |
KR20230012616A (ko) | 2020-05-20 | 2023-01-26 | 에이엠오 아일랜드 | 광학 활성 장치에 사용하기 위한 아자쿠마린 및 아자티오쿠마린 유도체 |
CN115960112B (zh) * | 2023-02-03 | 2024-02-20 | 北京大学深圳医院(北京大学深圳临床医学院) | 一种花椒毒醇衍生物及其制备方法和应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5729765A (en) | 1980-10-08 | 1982-02-17 | Yuuichi Yanagi | Melting of snow on roof |
US6861405B2 (en) | 2001-06-12 | 2005-03-01 | Yale University | Compositions and methods relating to glucose metabolism, weight control, and food intake |
AUPS127202A0 (en) | 2002-03-20 | 2002-04-18 | Walter And Eliza Hall Institute Of Medical Research, The | Therapeutic ion channel blocking agents and methods of use thereof |
US7772408B1 (en) | 2002-08-29 | 2010-08-10 | The Regents Of The University Of California | Substituted 5-alkoxypsoralens as inhibitors of potassium channel activity in lymphocytes and other cells |
AU2003288925A1 (en) | 2002-10-08 | 2004-05-04 | Massachusetts Institute Of Technology | Compounds for modulation of cholesterol transport |
ITPD20020325A1 (it) | 2002-12-18 | 2004-06-19 | Consorzio Interuniversitario Nazionale La Chimic | Sintesi di aniline funzionalizzate mono-n-sostituite. |
CN100486245C (zh) | 2003-07-31 | 2009-05-06 | 中兴通讯股份有限公司 | 一种支持多媒体消息版权保护的多媒体消息业务实现方法 |
US7557138B2 (en) * | 2004-10-04 | 2009-07-07 | The Regents Of The University Of California | 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel |
AU2006225071B2 (en) | 2005-03-15 | 2012-01-12 | The Regents Of The University Of California | Novel potassium channel blockers and uses thereof |
CA2619480A1 (fr) | 2005-08-17 | 2007-02-22 | Solvay Pharmaceuticals Gmbh | Methode d'utilisation de composes inhibiteurs du canal du potassium |
US20100239562A1 (en) | 2006-05-22 | 2010-09-23 | The Johns Hopkins University | Kv CHANNELS IN NEURODEGENERATION AND NEUROPROTECTION |
NZ575686A (en) | 2006-10-04 | 2012-02-24 | Bionomics Ltd | Novel chromenone potassium channel blockers and uses thereof |
US8309545B2 (en) | 2006-10-04 | 2012-11-13 | Bionomics Limited | Benzofuran potassium channel blockers and uses thereof |
CN101307056B (zh) * | 2007-05-16 | 2011-04-27 | 中国科学院上海药物研究所 | 线型呋喃香豆素衍生物、其制备方法和用途、以及包含该衍生物的药物组合物 |
US8202513B2 (en) | 2007-10-04 | 2012-06-19 | Bionomics Limited | Aryl potassium channel blockers and uses thereof |
WO2009061770A2 (fr) | 2007-11-07 | 2009-05-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Procédé d'inhibition de l'abcg2 et traitements associés |
JP2011522843A (ja) | 2008-06-13 | 2011-08-04 | バイオノミクス リミテッド | 新規なカリウムチャンネルブロッカー及びその使用 |
GB0815782D0 (en) | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
ES2345527B1 (es) | 2008-10-08 | 2011-09-08 | Hospital Clinic I Provincial De Barcelona | Sustancias bloqueadoras de los canales kv 1.3 para el tratamiento de enfermedades asociadas a hiperplasia de la intima. |
TW201026708A (en) | 2008-12-12 | 2010-07-16 | Solvay Pharm Bv | Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers |
WO2010130638A1 (fr) | 2009-05-14 | 2010-11-18 | Evotec Ag | Composés sulfamides, compositions pharmaceutiques et leurs utilisations |
AU2010295806B2 (en) | 2009-09-15 | 2013-12-19 | The Regents Of The University Of California | Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same |
CN102091067B (zh) | 2009-12-09 | 2013-04-10 | 中国科学院上海药物研究所 | 呋喃香豆素类化合物在制备药物中的新用途 |
WO2011073277A1 (fr) | 2009-12-16 | 2011-06-23 | Evotec Ag | Dérivés d'arylsulfonamides de pipéridine en tant que modulateurs de kv.1.3 |
WO2011073269A1 (fr) | 2009-12-16 | 2011-06-23 | Evotec Ag | Dérivés d'arylsulfonamides de pipéridine utilisés en tant que modulateurs de kv.1.3 |
WO2011073273A1 (fr) | 2009-12-16 | 2011-06-23 | Evotec Ag | Dérivés d'arylsulfonamides de benzoxazine en tant que modulateurs de kv.1.3 |
WO2012119072A2 (fr) | 2011-03-02 | 2012-09-07 | Bioincept, Llc | Compositions et procédés pour traiter des lésions intracellulaires |
EP2717871A4 (fr) * | 2011-06-09 | 2014-11-12 | Univ California | Réduction de la neurotoxicité médiée par la microglie par inhibition de kv1.3 |
IN2014CN03333A (fr) | 2011-10-03 | 2015-07-03 | Univ California | |
BR112018069854A2 (pt) * | 2016-03-31 | 2019-01-29 | Toray Industries | métodos para produzir proteína, xilo-oligossacarídeos e glicose, método para suprimir a diminuição na saturação de oxigênio dissolvido ao cultivar um fungo e composição de celulase |
-
2016
- 2016-03-11 TW TW105107667A patent/TWI701249B/zh not_active IP Right Cessation
- 2016-03-14 JP JP2017548004A patent/JP6506409B2/ja not_active Expired - Fee Related
- 2016-03-14 LT LTEP16709802.9T patent/LT3268374T/lt unknown
- 2016-03-14 DK DK16709802.9T patent/DK3268374T3/da active
- 2016-03-14 EA EA201791816A patent/EA037194B1/ru not_active IP Right Cessation
- 2016-03-14 CN CN201680015246.3A patent/CN107548397B/zh not_active Expired - Fee Related
- 2016-03-14 PL PL16709802T patent/PL3268374T3/pl unknown
- 2016-03-14 CA CA2979503A patent/CA2979503A1/fr not_active Abandoned
- 2016-03-14 UA UAA201709835A patent/UA121493C2/uk unknown
- 2016-03-14 EP EP16709802.9A patent/EP3268374B1/fr active Active
- 2016-03-14 US US15/557,696 patent/US10822345B2/en active Active
- 2016-03-14 RS RS20191621A patent/RS59758B1/sr unknown
- 2016-03-14 SG SG11201707284PA patent/SG11201707284PA/en unknown
- 2016-03-14 KR KR1020177025482A patent/KR20170137056A/ko not_active Application Discontinuation
- 2016-03-14 MX MX2017011650A patent/MX2017011650A/es active IP Right Grant
- 2016-03-14 AU AU2016232338A patent/AU2016232338B2/en not_active Ceased
- 2016-03-14 SI SI201630567T patent/SI3268374T1/sl unknown
- 2016-03-14 PT PT167098029T patent/PT3268374T/pt unknown
- 2016-03-14 BR BR112017019439-2A patent/BR112017019439A2/pt not_active IP Right Cessation
- 2016-03-14 ES ES16709802T patent/ES2762938T3/es active Active
- 2016-03-14 WO PCT/EP2016/055451 patent/WO2016146583A1/fr active Application Filing
-
2017
- 2017-08-16 ZA ZA2017/05561A patent/ZA201705561B/en unknown
- 2017-09-10 IL IL254391A patent/IL254391B/en active IP Right Grant
- 2017-09-11 PH PH12017501652A patent/PH12017501652B1/en unknown
-
2018
- 2018-03-12 HK HK18103372.2A patent/HK1243997B/zh unknown
-
2019
- 2019-02-13 US US16/274,748 patent/US10723743B2/en active Active
- 2019-12-13 CY CY20191101312T patent/CY1122470T1/el unknown
- 2019-12-16 HR HRP20192258TT patent/HRP20192258T1/hr unknown
-
2020
- 2020-07-09 US US16/924,750 patent/US20200339592A1/en not_active Abandoned
- 2020-08-18 US US16/996,502 patent/US20200377514A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1243997B (zh) | Kv1.3抑制劑及其醫學應用 | |
HK1251183A1 (zh) | 生物綴合物及其用途 | |
IL259570A (en) | Combined therapy and their uses and methods | |
GB201605126D0 (en) | Inhibitors and their uses | |
HK1252026A1 (zh) | 藥物組合及其應用 | |
SI3532459T1 (sl) | Zaviralci LSD1 in njihove medicinske uporabe | |
EP3317195A4 (fr) | Dispositifs et procédés intermodaux | |
IL255530A (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
HK1250926A1 (zh) | 抑制劑及其應用 | |
ZA201801134B (en) | Hydroxytriazine compound and medical use thereof | |
GB201709840D0 (en) | Methods and medical uses | |
EP3359151A4 (fr) | Inhibiteurs de la sumoylation de crmp2 et utilisations associées | |
GB201800471D0 (en) | Medical devices, systems, and methods utilizing antithrombin-heparin compositions | |
HK1243998A1 (zh) | Kv1.3抑制劑及其醫學應用 | |
GB201508028D0 (en) | Sandfalls and the like | |
GB201709837D0 (en) | Methods and medical uses | |
GB201719043D0 (en) | Methods and compounds | |
EP3243514A4 (fr) | Agent thérapeutique et/ou de prévention contre la fibromyalgie | |
GB201504770D0 (en) | Medical devices and methods | |
GB201505971D0 (en) | Inhibitors and their uses | |
GB201505975D0 (en) | Inhibitors and their uses |